CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany ...
"This work highlights the importance of further studies to know better the consequences of genetic variability on the long-range regulation of α-globin genes in humans." - Pena et al., Molecular ...
Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Alpha Thalassemia pipeline constitutes 3+ key companies continuously working towards developing 3+ ...
The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adults with non-transfusion-dependent (NTD) and ...
Agios Pharmaceuticals completed its IPO in 2013 and sold its oncology portfolio for $1.8bn in 2021. Its stock price is down 50% across a 5-year period. The company's focus is now on mitapivat, which ...
AMSTERDAM--(BUSINESS WIRE)-- Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios ...
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From ...
CHULA VISTA, Calif. — Nothing can prepare you for parenthood, and a local family was not ready to hear their unborn child may die or have life long complications. For Annemarie and Stephen, they were ...
Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ET CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a ...
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results